STOCKHOLM--(BUSINESS WIRE)--Regulatory News:In connection with the acquisition of Corvette Pharmaceutical Services Group completed on October 1, 2014, Recipharm AB (publ) (“Recipharm”)(STO:RECI) issued convertible bonds with a nominal value of EUR 50 million as part of the financing of the acquisition. The convertible bonds can be converted into up to 5,030,549 class B-shares. The holders of the convertible bonds have agreed to a lock-up in respect of the new shares issued upon conversion until 14 February, 2015.
Recipharm has received a request and has released the lock-up on 815,000 B-shares related to shares to be issued upon conversion of the convertible bonds. The release of the lock-up has been granted to facilitate the sale of 815,000 class B-shares to three Swedish and Finnish long-only fund managers.
Help employers find you! Check out all the jobs and post your resume.
Recipharm has received a request and has released the lock-up on 815,000 B-shares related to shares to be issued upon conversion of the convertible bonds. The release of the lock-up has been granted to facilitate the sale of 815,000 class B-shares to three Swedish and Finnish long-only fund managers.
Help employers find you! Check out all the jobs and post your resume.
